Q: The stock has had a good recovery. What do you see in its future?
Appreciate your insight.
Paul F.
Appreciate your insight.
Paul F.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Looking to take a position in UNH, would you consider it stable now for half position.Seems to have put in a good floor past week. Thanks Mike
Q: It was mentioned in the 31 March 2025 end quarterly report that the company is buying out some asset back from Endo for 100-mil plus inventory. Do you think that the asset which company purchased will do well as Endo acquired it and kept it. Now they are disposing it. Is company found them not valuable enough to generate good return? If that is the reason then why GUD bought it? Will GUD manage to generate good return out of it?
Thanks
Piyush
Thanks
Piyush
-
AbbVie Inc. (ABBV $220.08)
-
Procter & Gamble Company (The) (PG $141.87)
-
UnitedHealth Group Incorporated (DE) (UNH $343.98)
-
Elevance Health Inc. (ELV $372.83)
Q: Greetings Folks:
Given I am 79 years of age, do feel there are better options than waiting out UNH's revival? We are currently also invested in ElV.
Thanks millions for your great support!!!!
brian
Given I am 79 years of age, do feel there are better options than waiting out UNH's revival? We are currently also invested in ElV.
Thanks millions for your great support!!!!
brian
Q: Hello,
Any plans to update your research report on GUD now that they have bought back Paladin Labs?
Thankyou.
Any plans to update your research report on GUD now that they have bought back Paladin Labs?
Thankyou.
Q: Stock has been hammered while reportedly May 19th CEO and CFO collectively buy ~$30 mln worth of stock.
Lots of problems, do you believe the company can recover from its Medicare Advantage woes?
Thanks for all your great work! Ted.
Lots of problems, do you believe the company can recover from its Medicare Advantage woes?
Thanks for all your great work! Ted.
Q: I have a hard time evaluating biopharmaceutical firms save via technical analysis. Given that Structure Therapeutics is so "new", I am finding even this method difficult to rely on. What is your opinion of GPCR's prospects?
Q: What do you make of the news that QIPT has an offer to be taken private by Forager for $3.10 USD. What are your thoughts on its trading at $1.80USD..... the market clearly does not think this is going to happen or that a competing offer is likely. What is Qipt worth and does it make sense to hang on to see how this plays out?
A long suffering stock holder
A long suffering stock holder
Q: Would you be a buyer of ISRG at this time? If not, what price would you consider it to be buyable?
Q: Can I get your assessment of NGEN? Can the fundamentals support a sustained move in this one? That is some major volume coming in on those up days! Thanks.
Q: What is your opinion regarding the future of CRSP? Buy, sell, hold?
Q: There has been some insider buying on this stock lately by the new president ( 25 millions ) and by other directors, do you think it is a good idea to buy some shares and have a good risk reward potential or should we wait for more positive signs. I was thinking of going for a 2% position today. This company is so big and has a proven business model.
Q: Your view on their Q earnings announced last night would be appreciated, please and thank you.
Q: do you think it's a good time to start getting some of this stock? Is the Canadian or US side better? I see that 5i staff owns unh.us and I'm guessing that their ACB is higher than the current price.
Q: What is your thinking on ABBV. I've held it for years and am up nicely. With pending limits on US drug pricing (maybe) is this a time to sell or hold? Or add, for that matter. thanks
Q: Hey everyone, this 1b dollar company looks amazing to me. What am I missing? They have over 300 million in cash and are cash flow positive. This type of drug has been acknowledged recently as part of a drug regime that helps people with lupus nephritis its a calcinurin inhibitor.
How would you value this company? the market doesn’t like it even though it’s making 260million a year going forward with no debt. Is there an issue with the IP?
How would you value this company? the market doesn’t like it even though it’s making 260million a year going forward with no debt. Is there an issue with the IP?
Q: The market is more complicated than ever. Taking into consideration that we have had a big bounce from lows, what sector right now would you say offers the most value, where a year from now we will say, "wow, that was a real buying opportunity?" Any screaming buys? Thank you!
Q: Healthcare is doing terribly. When this happens should one sell positions or just hold good companies into the decline knowing the tide can turn at any time. I have a hard time knowing if I should be selling companies in sectors that are not working and reallocating money to say financials or industrials. Thank you!
Q: VHT is hitting some lows, being effected by UNH which is a 4.7% position of the fund. Do you see upside from here, or is it a cautionary sector right now? How do you see the sector going forward? Thinking of stepping in as my healthcare part of portfolio is low. Thanks.
-
The Cigna Group (CI $278.95)
-
Teladoc Health Inc. (TDOC $7.46)
-
WELL Health Technologies Corp. (WELL $4.23)
-
Elevance Health Inc. (ELV $372.83)
Q: Hi there, wouldn't it be worthwhile for some to takeover WELL now, by paying a real good premium to todays price and yet... still scoop up WELL on the cheap, based on its future potential and better execution with new management/board?
If so, who do you feel would want to take over WELL?
What would be a good takeover price based on Q1 results and 2025 forward guidance?
Thanks!
If so, who do you feel would want to take over WELL?
What would be a good takeover price based on Q1 results and 2025 forward guidance?
Thanks!